Verona Pharma
VRNA
VRNA was delisted on the 6th of October, 2025.
191 hedge funds and large institutions have $3.19B invested in Verona Pharma in 2024 Q4 according to their latest regulatory filings, with 54 funds opening new positions, 57 increasing their positions, 59 reducing their positions, and 13 closing their positions.
325% more call options, than puts
Call options by funds: $71.2M | Put options by funds: $16.7M
315% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 13
109% more funds holding in top 10
Funds holding in top 10: 11 → 23 (+12)
63% more capital invested
Capital invested by funds: $1.95B → $3.19B (+$1.24B)
27% more funds holding
Funds holding: 150 → 191 (+41)
0.07% more ownership
Funds ownership: 10.41% → 10.48% (+0.07%)
3% less repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 59
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SPPAM
Summit Partners Public Asset Management
Boston,
Massachusetts
|
+$71.4M |
| 2 |
RI
RTW Investments
New York
|
+$68.4M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$43M |
| 4 |
Morgan Stanley
New York
|
+$33.5M |
| 5 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
+$30.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$122M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$87.5M |
| 3 |
VC
Vivo Capital
Palo Alto,
California
|
-$47.5M |
| 4 |
OCA
Octagon Capital Advisors
New York
|
-$47.5M |
| 5 |
MC
Maverick Capital
Dallas,
Texas
|
-$40.8M |
VRNA Hedge Fund Activity: Q4 2024 in Review
191 of the 7,494 institutional investors tracked by Wall St. Rank reported a position in Verona Pharma (VRNA) for Q4 2024, worth a combined $3.19B — up 63% from $1.95B a quarter earlier.
Buyers outnumbered sellers: 54 funds opened new VRNA positions and 13 closed out — a net gain of 41 holders — while 57 added to existing stakes and 59 trimmed.
The largest buyer was Summit Partners Public Asset Management, opening a new position worth an estimated $71.4M. The largest seller was RA Capital Management, cutting an estimated $122M.
- 191 institutional investors held Verona Pharma (VRNA) as of Q4 2024, up from 150 in Q3 2024.
- Funds reported $3.19B of Verona Pharma stock for Q4 2024, up 63% quarter-over-quarter.
- 54 funds opened new Verona Pharma positions in Q4 2024 and 13 closed out, a net change of +41 holders.
- The largest Verona Pharma buyer in Q4 2024 was Summit Partners Public Asset Management, an estimated $71.4M added.
- The largest Verona Pharma seller in Q4 2024 was RA Capital Management, an estimated $122M sold.
Based on aggregated 13F filings for Q4 2024.